small molecule inhibition kras-pde delta interaction impairs oncogenic kras signalling 
kras oncogene product considered major target anticancer drug discovery1- however direct interference kras signalling yet led clinically useful drugs3- correct localization signalling farnesylated kras regulated prenyl-binding protein pde delta sustains spatial organization kras facilitating diffusion cytoplasm9- report interfering binding mammalian pded kras means small molecules provides novel opportunity suppress oncogenic ras signalling altering localization endomembranes biochemical screening subsequent structure-based hit optimization yielded inhibitors kras-pde delta interaction selectively bind prenyl-binding pocket pde delta nanomolar affinity inhibit oncogenic ras signalling suppress vitro vivo proliferation human pancreatic ductal adenocarcinoma cells dependent oncogenic kras findings may inspire novel drug discovery efforts aimed development drugs targeting oncogenic ras 
